Credit Suisse Group Analysts Give Homology Medicines (NASDAQ:FIXX) a $3.10 Price Target

Credit Suisse Group set a $3.10 price target on Homology Medicines (NASDAQ:FIXXGet Rating) in a research report sent to investors on Monday, Stock Target Advisor reports.

A number of other equities analysts have also recently issued reports on FIXX. Oppenheimer cut shares of Homology Medicines from an outperform rating to a market perform rating in a research report on Tuesday, February 22nd. Canaccord Genuity Group cut their price objective on shares of Homology Medicines from $19.00 to $7.00 and set a buy rating for the company in a research report on Wednesday, April 6th. BTIG Research cut their price objective on shares of Homology Medicines from $35.00 to $29.00 and set a neutral rating for the company in a research report on Tuesday, February 22nd. Chardan Capital cut their price objective on shares of Homology Medicines to $14.00 and set a na rating for the company in a research report on Tuesday, May 17th. Finally, HC Wainwright reissued a buy rating and issued a $20.00 price objective on shares of Homology Medicines in a research report on Monday, May 23rd. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus target price of $13.01.

Shares of FIXX opened at $2.25 on Monday. The stock has a market cap of $129.12 million, a P/E ratio of -28.12 and a beta of -0.20. The company has a 50-day moving average of $1.75 and a two-hundred day moving average of $2.91. Homology Medicines has a 12-month low of $1.30 and a 12-month high of $8.90.

Homology Medicines (NASDAQ:FIXXGet Rating) last announced its earnings results on Monday, May 16th. The company reported $1.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.10. Homology Medicines had a negative net margin of 47.29% and a negative return on equity of 49.48%. Research analysts predict that Homology Medicines will post -1.86 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of FIXX. Arizona State Retirement System acquired a new position in Homology Medicines during the first quarter worth approximately $31,000. Dimension Capital Management LLC acquired a new stake in shares of Homology Medicines in the fourth quarter worth $40,000. Raymond James & Associates acquired a new stake in shares of Homology Medicines in the first quarter worth $51,000. Mirabella Financial Services LLP acquired a new stake in shares of Homology Medicines in the first quarter worth $53,000. Finally, PDT Partners LLC acquired a new stake in shares of Homology Medicines in the fourth quarter worth $58,000. 58.14% of the stock is owned by hedge funds and other institutional investors.

Homology Medicines Company Profile (Get Rating)

Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders.

Featured Articles

Analyst Recommendations for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.